Merck & Co., Inc. (NYSE:MRK) Shares Bought by V Square Quantitative Management LLC

V Square Quantitative Management LLC increased its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 25.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 52,745 shares of the company’s stock after buying an additional 10,614 shares during the quarter. Merck & Co., Inc. comprises about 1.2% of V Square Quantitative Management LLC’s holdings, making the stock its 11th biggest position. V Square Quantitative Management LLC’s holdings in Merck & Co., Inc. were worth $6,960,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRK. Vermillion & White Wealth Management Group LLC acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $27,000. Bare Financial Services Inc acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $28,000. Burkett Financial Services LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $30,000. Finally, RIA Advisory Group LLC bought a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $30,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 0.2 %

Shares of Merck & Co., Inc. stock traded down $0.21 on Tuesday, hitting $130.78. 6,254,129 shares of the company traded hands, compared to its average volume of 8,049,210. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $133.10. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The company has a market cap of $331.24 billion, a PE ratio of 145.31, a PEG ratio of 1.68 and a beta of 0.39. The company has a 50-day moving average price of $127.60 and a 200 day moving average price of $119.23.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.21 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. Sell-side analysts predict that Merck & Co., Inc. will post 8.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on MRK shares. UBS Group increased their price objective on Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 target price on shares of Merck & Co., Inc. in a report on Thursday, April 18th. Truist Financial lifted their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. TheStreet lowered shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Finally, Berenberg Bank lifted their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $131.33.

Check Out Our Latest Report on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.